|
|
- MHRA (Medicines) Drug Alerts (Various Recipients)
- Other contacts
- Independent Healthcare Providers (registered with CAS)
- Clinical Commissioning Groups
- NHS Foundation Trusts (England) - Medical Director
- NHS Foundation Trusts (England) - Chief Executive
- NHS Trusts (England) - Medical Director
- CMO Urgent Messages - Non-NHS Recipients on Public Health Link
- MHRA (Medicines) Drug Alerts - Non-NHS Recipients
- Territorial CMOs in Northern Ireland, Scotland & Wales
- Regional Directors of Public Health
- Consultants in Communicable Diseases
- CMO Urgent Messages - Recipients on Public Health Link
- Director of Public Health
- NHS Trusts (England) - Chief Executive
|
| Title: |
|
Neutralising monoclonal antibodies in the treatment of COVID-19 in hospitalised patients
|
| Broadcast content: |
|
The previously published policy providing access to neutralising monoclonal antibodies (nMABs) for hospitalised patients with COVID infection has been updated to reflect the availability of sotrovimab (Xevudy) for use in the UK from the week commencing 20 December. Changes have also been made because it is understood that the efficacy of the combination monoclonal antibody casirivimab and imdevimab (Ronapreve), included in the original policy, is likely to be materially compromised against the increasingly prevalent Omicron variant.
|
| Additional information: |
|
This alert does not need to be cascaded to Primary Care.
|